RXi Pharmaceuticals
Investor & Analyst Symposium

Agenda

10:45-11:15am Arrival, Registration, Buffet

11:15am Welcome & Introduction
   – Dr. Geert Cauwenbergh

11:20am Abnormal scarring: The biology
   – Dr. Leroy Young

11:35am Abnormal scarring: The patient needs
   – Dr. Jeannette Graf

11:50am RXI-109: Safety/Side effects
   – Dr. Lyn Libertine

12:15pm RXI-109: Pharmacokinetics
   – Karen Bulock, Ph.D.

12:35pm RXI-109: Pharmacodynamics
   – Karen Bulock, Ph.D.

12:55pm RXI-109: Preliminary clinical observations
   – Dr. Geert Cauwenbergh

1:20pm RXI-109 Phase 2 plans and other opportunities and therapeutic areas
   – Pam Pavco, Ph.D.

1:45pm Conclusion and closing remarks
   – Dr. Geert Cauwenbergh

A replay of this presentation/webcast will be available for 90 days and may be accessed on the company’s website: www.rxipharma.com/investors/events
Speaker Biographies

**Geert Cauwenbergh, Dr. Med. Sc.**
Dr. Cauwenbergh was appointed President and Chief Executive Officer of RXi Pharmaceuticals Corporation in April of 2012. Prior to joining RXi, Dr. Cauwenbergh served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President, Research and Development for Johnson & Johnson’s Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. Dr. Cauwenbergh received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.

**Pamela A. Pavco, Ph.D.**
Dr. Pavco currently serves as Chief Development Officer for RXi Pharmaceuticals, Corporation. Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck & Co., Inc. for $1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna-027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirna’s alliance with Allergan, Inc. that was initiated to continue discovery research in the area of ophthalmology and take Sirna-027 forward into Phase 2 clinical studies. While at Sirna, Dr. Pavco served in various additional capacities, including Director of Biology Research and Director of Pharmacology and she also managed numerous corporate collaborations and internal programs focusing on the development of therapeutic oligonucleotides in the fields of oncology, anti-angiogenesis, hepatitis, respiratory disease and Huntington’s disease. Dr. Pavco received a Ph.D. in Biochemistry from Virginia Commonwealth University in 1983 and did her post-doctoral work at Duke University. She is a member of the American Association of Cancer Research and the Association for Research and Vision in Ophthalmology.

**Lyn Libertine, M.D.**
Dr. Libertine currently serves as Vice President Medical Affairs & Safety Assessment for RXi Pharmaceuticals, Corporation. Dr. Libertine spent 5 years at Critical Therapeutics, Inc., which was acquired by Cornerstone Therapeutics Inc., where she was an integral member of the development team responsible for filing the sNDA for Zyflo, an oral medication for the treatment of asthma. Prior to joining Critical Therapeutics, she held various research positions in pharmacology and toxicology at CytoMed, Inc., which was acquired by UCB Pharma in 2000. Dr. Libertine did her undergraduate work in Chemistry and Biology at Boston University and received her medical degree at the University of Massachusetts. Dr. Libertine is a member of the American Medical Association, Massachusetts Medical Society, American Chemical Society, American Thoracic Society and the Association for Research and Vision in Ophthalmology.
Karen Bulock, Ph.D.
Dr. Bulock currently serves as Vice President Research for RXi Pharmaceuticals, Corporation. Dr. Bulock has over twenty years of experience in assay development and discovery project management. Since joining RXi in 2011, and previously while at Galena, Dr. Bulock has managed several key programs, including the discovery and preclinical development of RXI-109, RXi’s first clinical candidate. Prior to joining RXi, Dr. Bulock spent several years leading assay development and screening projects to support small molecule drug discovery programs in the fields of metabolic disease and anti-infectives at CytRx Corporation and Essential Therapeutics, Inc. Dr. Bulock received a Ph.D. in Pharmacology from Yale University. Dr. Bulock has authored numerous scientific articles and is a co-inventor on four patent applications.

Leroy Young, M.D.
Dr. Young is the Director of the BodyAesthetic Research Center in St. Louis, Missouri. Dr. Young is the immediate past President of the Aesthetic Surgery Education and Research Foundation (ASERF) and serves on multiple leadership committees, most recently those focused on his interests in patient safety, clinical research, emerging trends, and innovative procedures. As a member of ASERF, the American Society for Aesthetic Plastic Surgery (ASAPS), and the Plastic Surgery Educational Foundation (PSEF) he has received numerous honors, including a Distinguished Service Award from ASERF in May 2009. His clinical research activity has included trials with Botulinum Toxin Type A, Sodium and Deoxycholate injections, as well as with the antisense oligonucleotide EXC-001 for the treatment of scars and Avotermia (Juvista) for scar management. Dr. Young is Board certified in General Surgery and Plastic Surgery. More than 150 of his articles have been published in peer-reviewed journals since 1976, and he has contributed chapters to more than 25 books. Dr. Young did his residency in general surgery at the University of Kentucky Medical Center in Lexington, and his residency in plastic surgery at the Barnes Hospital, Washington University School of Medicine, St. Louis Missouri, where he graduated in 1979.

Jeannette Graf, M.D.
Dr. Jeannette Graf is a board certified, clinical and research Dermatologist. She is an Assistant Clinical Professor of Dermatology at the Mount Sinai School of Medicine. Prior to completing her Residency in Dermatology at the New York University Medical Center, Dr. Graf earned her medical degree from the State University of New York – School of Medicine at Buffalo. Committed to research and the science of natural ingredients from an early point in her career, Dr. Graf was a research fellow and protégé of George Martin, Ph.D., lab chief and one of the most highly respected scientists in the world, at the National Institutes of Health (NIH). Dr. Graf serves as an independent consultant and advisory board member for a number of cosmetic and pharmaceutical companies including RXi Pharmaceuticals Corporation, Neutrogena, Johnson & Johnson, RoC, Allergan, Aveeno, Merz/Bioform and Medicis. She performed some of the earliest studies on soy technology used in the Aveeno product line and participated in its successful market launch. Dr. Graf also serves on the educational faculty of Allergan and Medicis, where she lectures and teaches other aesthetic physicians how to inject Botox and Restylane, and serves on the editorial board of Modern Aesthetics. She has published in prestigious journals such as Cell, Science, the Journal of Cell Biology and the Proceedings of the National Academy of Sciences. Dr. Graf has been in private practice since 1990 in Great Neck, New York.